Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Vizimpro (Dacomitinib).
Birth control: Use effective birth control while using Vizimpro (Dacomitinib), as Vizimpro (Dacomitinib) may harm the baby if used during pregnancy. Both men and women should use effective birth control (e.g., condoms, birth control pill) during treatment and for at least 2 months after treatment is finished. If you or your partner become pregnant while taking Vizimpro (Dacomitinib), contact your doctor immediately.
Diarrhea: Vizimpro (Dacomitinib) commonly causes diarrhea, which, if it is severe, can lead to dehydration because of fluid loss. While you are taking Vizimpro (Dacomitinib), make sure you are drinking plenty of fluids. If you experience diarrhea, talk to your doctor. Severe dehydration can cause rapid loss of kidney function and is a medical emergency. If you experience symptoms of dehydration such as decreased tears, sweating, urine production, constipation, headache, or muscle cramps, seek medical attention.
Eye problems: You may experience changes in vision while taking Vizimpro (Dacomitinib). Tell your doctor if you experience eye pain or redness, or any vision disturbances, such as flashes of light, blurry vision, or double vision.
Liver function: Vizimpro (Dacomitinib) may reduce liver function and can cause liver problems. Your doctor will monitor your liver function with blood tests while you are taking Vizimpro (Dacomitinib). If you have liver problems, discuss with your doctor how Vizimpro (Dacomitinib) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Vizimpro (Dacomitinib), and whether any special monitoring is needed.
If you experience symptoms of liver problems such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin, contact your doctor immediately.
Lung inflammation: Some people taking Vizimpro (Dacomitinib) have experienced lung inflammation (interstitial lung disease) causing difficulty breathing. This complication can be serious and sometimes fatal. If you experience new or worsening shortness of breath or cough (with or without fever) at any time while you are taking Vizimpro (Dacomitinib), contact your doctor immediately.
Nail changes: Vizimpro (Dacomitinib) can cause infection of the skin surrounding the fingernails or toenails. It is important to keep your hands and feet clean and dry, be gentle when trimming your nails and avoid injury to the nails or finger tips. Use gentle soaps and nail products, avoiding harsh soaps and detergents with chemicals. If you experience symptoms of an infection of the nail or nailbed, such as redness, swelling, heat, or pain, contact your doctor as soon as possible.
Skin changes: Vizimpro (Dacomitinib) can cause changes to the skin, making it dry or red, and can cause acne and peeling. Blisters may form on the palms of the hands and soles of the feet. Applying a good moisturizer to the skin from the time you start taking Vizimpro (Dacomitinib) may help to reduce how severe these effects become. If you experience blistering or peeling skin, report this to your doctor as soon as possible.
Vizimpro (Dacomitinib) may increase the sensitivity of the skin to sunlight, increasing the risk of Sunburn. Avoid exposure to sunlight for long periods of time, particularly between the hours of 10 am and 2 pm, while you are taking Vizimpro (Dacomitinib). Wear a broad-spectrum sunscreen and lip balm with an SPF of 30 or greater. If you notice any unusual skin rash or peeling, contact your doctor immediately.
Pregnancy: Although the safety and effectiveness of Vizimpro (Dacomitinib) when used during pregnancy haven’t been determined, it is expected that it is likely to cause harm to an unborn baby if it is taken by the mother during pregnancy. If you become pregnant while taking Vizimpro (Dacomitinib), contact your doctor immediately.
Breast-feeding: It is not known if Vizimpro (Dacomitinib) passes into breast milk. If you are a breast-feeding mother and are taking Vizimpro (Dacomitinib), it may affect your baby. Due to the risk of serious harm to a baby if they are exposed to Vizimpro (Dacomitinib), breast-feeding mothers are advised not to use Vizimpro (Dacomitinib). In addition, breast-feeding should not be started until at least 2 months after taking the last dose of Vizimpro (Dacomitinib).
Children: The safety and effectiveness of using Vizimpro (Dacomitinib) have not been established for children and adolescents less than 18 years of age.
Seniors: People over the age of 65 may experience side effects of Vizimpro (Dacomitinib).
